LATISSE

LOE Approaching

bimatoprost

NDATOPICALSOLUTION/DROPSPriority Review
Approved
Dec 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

analog. Although the precise mechanism of action is unknown, the growth of eyelashes is believed to occur by increasing the percent of hairs in, and the duration of the anagen or growth phase.

Pharmacologic Class:

Prostaglandin Analog

Clinical Trials (5)

NCT05729594Phase 1Completed

Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers

Started Feb 2023
NCT05397600Phase 3Completed

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Started Jun 2022
NCT04647214N/ACompleted

18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)

Started Mar 2021
220 enrolled
Open-angle GlaucomaOcular Hypertension
NCT04285580Phase 3Completed

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Started Jun 2020
37 enrolled
Open-Angle GlaucomaOcular Hypertension
NCT03891446Phase 3Active Not Recruiting

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

Started Mar 2019
455 enrolled
Open-Angle GlaucomaOcular Hypertension